Pre-made Rovalpituzumab benchmark antibody ( Whole mAb ADC, anti-DLL3 therapeutic antibody, Anti-SCDO1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Rovalpituzumab biosimilar, Whole mAb ADC, Anti-DLL3 Antibody: Anti-SCDO1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie.[3] It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-497-1mg	1mg	Inquiry
GMP-Bios-ab-497-10mg	10mg	Inquiry
GMP-Bios-ab-497-100mg	100mg	Inquiry
GMP-Bios-ab-497-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Rovalpituzumab biosimilar, Whole mAb ADC, Anti-DLL3 Antibody: Anti-SCDO1 therapeutic antibody
INN Name	Rovalpituzumab
Target	DLL3
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Bristol-Myers Squibb;Stemcentrx
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Small cell lung cancer;Solid tumours
Development Tech	na